Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Benjamin D. Greenbaum

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6153-8793; OpenAlex author ID A5063215100; NIH RePORTER profile ID 10520786. Sources: OpenAlex.

Their work

Papers
10
Trials
0
Grants
1
Labs led
0
Collaborators
73
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 3 papers · 2026: 2 papers, 1 grant

Papers 10

  1. POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer Co-author DOI 10.64898/2026.03.15.711961↗
  2. Neoantigen-reactive CD8 + T cell engagement marks exceptional survivors of pancreatic cancer Co-author DOI 10.64898/2026.09.17.752426↗
  3. IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer. Co-author DOI 10.1038/s41586-024-08426-5↗
  4. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Co-author DOI 10.1038/s41586-024-08508-4↗
  5. LINE-1 ORF1p Mimics Viral Innate Immune Evasion Mechanisms in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/2159-8290.cd-24-1317↗
  6. Disruption of cellular plasticity by repeat RNAs in human pancreatic cancer. Co-author DOI 10.1016/j.cell.2024.09.024↗
  7. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Co-author DOI 10.1038/s41586-023-06063-y↗
  8. Neoantigen quality predicts immunoediting in survivors of pancreatic cancer. Co-author DOI 10.1038/s41586-022-04735-9↗
  9. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. Co-author DOI 10.1038/s43018-021-00269-7↗
  10. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Co-author DOI 10.1038/nature24462↗

Grants 1

  1. Optimization of structure-guided models of peptide presentation and T-cell receptor specificity R01CA318448↗

Closest collaborators

The 25 strongest of 73 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Quaid Morris · 1 shared grant, 2026 · strength 1.26
  2. Vinod P. Balachandran · 6 shared papers, 2017–2026 · strength 0.83
  3. Kevin C. Soares · 5 shared papers, 2022–2026 · strength 0.79
  4. Olca Baştürk · 4 shared papers, 2017–2026 · strength 0.57
  5. Wungki Park · 3 shared papers, 2025–2026 · strength 0.52
  6. Eileen Mary O'Reilly · 3 shared papers, 2025–2026 · strength 0.52
  7. Christine A. Iacobuzio–Donahue · 4 shared papers, 2017–2026 · strength 0.52
  8. Taha Merghoub · 4 shared papers, 2017–2025 · strength 0.46
  9. David Tsai Ting · 3 shared papers, 2021–2025 · strength 0.44
  10. Zachary M. Sethna · 3 shared papers, 2022–2025 · strength 0.42
  11. Luis Alfonso Rojas · 3 shared papers, 2022–2025 · strength 0.42
  12. Masataka Amisaki · 3 shared papers, 2022–2025 · strength 0.42
  13. Marinela Capanu · 2 shared papers, 2026 · strength 0.37
  14. Dana Pe'er · 2 shared papers, 2026 · strength 0.37
  15. Benoı̂t Rousseau · 2 shared papers, 2026 · strength 0.37
  16. Marc Hilmi · 2 shared papers, 2026 · strength 0.37
  17. Nuray Tezcan · 2 shared papers, 2026 · strength 0.37
  18. Fiyinfolu O. Balogun · 2 shared papers, 2026 · strength 0.37
  19. Kenneth H. Yu · 2 shared papers, 2026 · strength 0.37
  20. Siyu Sun · 2 shared papers, 2024–2025 · strength 0.35
  21. Eunae You · 2 shared papers, 2024–2025 · strength 0.35
  22. Anna M. Varghese · 2 shared papers, 2025–2026 · strength 0.34
  23. Alice Chia-Chi Wei · 2 shared papers, 2025–2026 · strength 0.34
  24. Akihiro Ohmoto · 2 shared papers, 2025 · strength 0.32
  25. Jedd D. Wolchok · 3 shared papers, 2017–2025 · strength 0.30

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.